➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Merck
McKinsey
Express Scripts
Dow
McKesson
Mallinckrodt

Last Updated: September 29, 2020

DrugPatentWatch Database Preview

Details for Patent: 4,816,470

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

Summary for Patent: 4,816,470
Title: Heterocyclic compounds
Abstract:Indole derivatives of the general formula (I) are disclosed: ##STR1## where R.sub.1 is H or an alkyl or alkenyl group, R.sub.2 is H, or an alkyl, alkenyl, aryl, aralkyl or cycloalkyl group; R.sub.3 is H or an alkyl group; R.sub.4 and R.sub.5 are independently H or an alkyl or propenyl group or together form an aralkylidene group; and Alk is an optionally substituted alkylene chain; and their physiologically acceptable salts and solutes. These compounds are potentially useful for the treatment of migraine and may be formulated as pharmaceutical compositions in conventional manner. Various methods for the production of the compounds are disclosed including a Fischer-indole cyclization process.
Inventor(s): Dowle; Michael D. (Hertford, GB2), Coates; Ian H. (Hertford, GB2)
Assignee: Glaxo Group Limited (
Application Number:06/789,831
Patent Claim Types:
see list of patent claims
Compound; Use; Composition;

Drugs Protected by US Patent 4,816,470

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

Foreign Priority and PCT Information for Patent: 4,816,470

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
United Kingdom8216526Jun 07, 1982

International Family Members for US Patent 4,816,470

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Austria 381933   Start Trial
Austria A208483   Start Trial
Australia 1544183   Start Trial
Australia 566149   Start Trial
Belgium 896986   Start Trial
Canada 1199643   Start Trial
Switzerland 657359   Start Trial
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Express Scripts
Harvard Business School
Merck
Mallinckrodt
Johnson and Johnson
AstraZeneca

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.